Wong Roy Kingsley, Harrington Jenny, Stevenson Annabel Irene
Faculty of Health and Medical Sciences, University of Adelaide, Adelaide, South Australia, Australia.
Division of Endocrinology, Women's and Children's Hospital, Adelaide, South Australia, Australia.
Australas J Dermatol. 2024 Dec;65(8):601-609. doi: 10.1111/ajd.14360. Epub 2024 Aug 8.
In recent years, there has been an increasing recognition of the unique healthcare needs of gender-diverse patients in Australia. With the continuous growth of referrals to gender health services, there is an increased demand for specialised dermatological care. There is still a significant knowledge gap and a lack of guidelines specifically tailored to this patient group. In this article, we will provide a brief overview of the journey of Transgender and Gender Diverse (TGD) individuals as they embark on psychological and pharmacologic treatment for gender dysphoria in Australia. We endeavour to contribute to the existing body of knowledge by examining the evidence surrounding the treatment of skin, hair and nail issues for TGD patients. This article will outline how dermatologists can assist in the care of the gender-diverse patient. Although puberty blockade (stage 1 treatments) has minimal dermatological impact, gender-affirming pharmacotherapy (stage 2 treatments) can lead to many dermatological issues including acne, patterned hair loss (PHL) and dermatitis. The dermatologist may also play a role in stage 3 treatments which include surgical or procedural interventions for gender affirmation.
近年来,澳大利亚对性别多元化患者独特的医疗保健需求的认识日益提高。随着转介至性别健康服务机构的人数不断增加,对专业皮肤科护理的需求也在上升。对于这一患者群体,目前仍存在显著的知识差距且缺乏专门制定的指南。在本文中,我们将简要概述澳大利亚跨性别者和性别多元化(TGD)个体在开始针对性别焦虑症进行心理和药物治疗时的历程。我们试图通过审视围绕TGD患者皮肤、毛发和指甲问题治疗的证据,为现有知识体系做出贡献。本文将概述皮肤科医生如何协助护理性别多元化患者。虽然青春期阻断(第一阶段治疗)对皮肤科的影响极小,但性别肯定性药物治疗(第二阶段治疗)可能导致许多皮肤问题,包括痤疮、型态性脱发(PHL)和皮炎。皮肤科医生在第三阶段治疗中也可能发挥作用,第三阶段治疗包括用于性别肯定的手术或程序性干预。